Boji Medical subsidiary secures drug registration for colon cleansing product

Boji Medical & Biotechnological Co., Ltd. announced its wholly-owned subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has obtained a drug registration certificate from the National Medical Products Administration. The certificate is for "Compound Polyethylene Glycol Electrolytes Powder (III)."

This chemical drug, a compound preparation for colon cleansing in adult patients, is indicated for use before endoscopy, radiological examination, or colon surgery. The registration certificate, with approval number H20255557, is valid until September 22, 2030.

According to market data, sales of the product in urban and county-level public hospitals in China are approximately RMB 220m for 2024.

Boji Medical stated that while the certificate confirms compliance with national drug review technical standards and enables production and sales, it does not anticipate a material impact on its operating performance. The company will disclose further developments as required.